A Conversation on the Future of Health Tech & Innovation
Start your day with the people shaping tomorrow’s healthcare innovations. Join Foley & Lardner, Silicon Valley Bank and CVS Health Ventures for a curated Female Founders & Funders Breakfast bringing together the builders, backers, and boundary pushers shaping the next wave of health tech and innovation.
You’ll walk away with:
- Insight you can act on today from operators, innovators, and investors
- A calibrated view of the 2026 trends reshaping health tech and innovation
- New relationships with people solving similar challenges
- Clarity on where the market is heading — and where the real opportunities lie
Speakers:
Alicia Dorner, Partner, Foley & Lardner
Alyssa Reisner, Partner & Executive Director, CVS Health Ventures
Kaitlin Berube, Managing Director – Startup Banking Life Science/Healthcare and Fintech, Silicon Valley
Related Insights
April 9, 2026
Health Care Law Today
Hemp Product Use in Medicare: CMS Greenlights Pilot Program under the Substance Access Beneficiary Engagement Incentive
On April 1, 2026, the Centers for Medicare & Medicaid Services (CMS), through the CMS Innovation Center (CMMI), officially launched a new pilot program which allows participants in specific CMS programs to offer eligible hemp products to eligible Medicare beneficiaries.
April 9, 2026
PharmaPatents
USPTO to Take a Piercing Look at National Stage Applications
USPTO’s PIER pilot program adds a new “confirm‑to‑proceed” step for selected U.S. national stage applications. The PIER program may increase costs, cause delays, and reduce patent term adjustment (PTA). The USPTO may benefit by reducing its workload without refunding examination fees.
April 9, 2026
Health Care Law Today
Structuring Discounts Arrangements in Compliance with Federal Anti-Kickback Law: OIG's Advisory Opinion 25-11
Understanding the regulatory framework for discount arrangements is essential in order to structure such arrangements to be in compliance with the AKS. The recent Office of lnspector General (OIG) Advisory Opinion 25-11 (AO 25-11) provided new insights and flexibilities on structuring discount arrangements and offered some of the most detailed guidance articulated by the OIG regarding permissible discount practices.